Literature DB >> 23032555

Mexiletine for treatment of myotonia: a trial triumph for rare disease networks.

Eric P Hoffman, Henry J Kaminski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23032555      PMCID： PMC4352340          DOI： 10.1001/jama.2012.12906

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  11 in total

Review 1.  Overexcited or inactive: ion channels in muscle disease.

Authors:  E P Hoffman; F Lehmann-Horn; R Rüdel
Journal:  Cell       Date:  1995-03-10       Impact factor: 41.582

2.  Improved therapy of myotonia with the lidocaine derivative tocainide.

Authors:  R Rüdel; R Dengler; K Ricker; A Haass; W Emser
Journal:  J Neurol       Date:  1980       Impact factor: 4.849

3.  Mexiletine block of disease-associated mutations in S6 segments of the human skeletal muscle Na(+) channel.

Authors:  M P Takahashi; S C Cannon
Journal:  J Physiol       Date:  2001-12-15       Impact factor: 5.182

Review 4.  Implementing clinical trials on an international platform: challenges and perspectives.

Authors:  Greg Minisman; Minal Bhanushali; Robin Conwit; Gil I Wolfe; Inmaculada Aban; Henry J Kaminski; Gary Cutter
Journal:  J Neurol Sci       Date:  2011-11-01       Impact factor: 3.181

5.  An interactive voice response diary for patients with non-dystrophic myotonia.

Authors:  Jeffrey M Statland; Yunxia Wang; Rachel Richesson; Brian Bundy; Laura Herbelin; Joe Gomes; Jaya Trivedi; Shannon Venance; Anthony Amato; Michael Hanna; Robert Griggs; Richard J Barohn
Journal:  Muscle Nerve       Date:  2011-07       Impact factor: 3.217

6.  The MGTX experience: challenges in planning and executing an international, multicenter clinical trial.

Authors:  Inmaculada B Aban; Gil I Wolfe; Gary R Cutter; Henry J Kaminski; Alfred Jaretzki; Greg Minisman; Robin Conwit; John Newsom-Davis
Journal:  J Neuroimmunol       Date:  2008-09-15       Impact factor: 3.478

7.  Mexiletine block of wild-type and inactivation-deficient human skeletal muscle hNav1.4 Na+ channels.

Authors:  Ging Kuo Wang; Corinna Russell; Sho-Ya Wang
Journal:  J Physiol       Date:  2003-11-07       Impact factor: 5.182

8.  Effect sizes for interpreting changes in health status.

Authors:  L E Kazis; J J Anderson; R F Meenan
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

Review 9.  The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment.

Authors:  E Matthews; D Fialho; S V Tan; S L Venance; S C Cannon; D Sternberg; B Fontaine; A A Amato; R J Barohn; R C Griggs; M G Hanna
Journal:  Brain       Date:  2009-11-16       Impact factor: 13.501

10.  Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial.

Authors:  Jeffrey M Statland; Brian N Bundy; Yunxia Wang; Dipa Raja Rayan; Jaya R Trivedi; Valeria A Sansone; Mohammad K Salajegheh; Shannon L Venance; Emma Ciafaloni; Emma Matthews; Giovanni Meola; Laura Herbelin; Robert C Griggs; Richard J Barohn; Michael G Hanna
Journal:  JAMA       Date:  2012-10-03       Impact factor: 56.272
View more
  6 in total

1.  Bioisosteric Modification of To042: Synthesis and Evaluation of Promising Use-Dependent Inhibitors of Voltage-Gated Sodium Channels.

Authors:  Gualtiero Milani; Maria Maddalena Cavalluzzi; Concetta Altamura; Antonella Santoro; Mariagrazia Perrone; Marilena Muraglia; Nicola Antonio Colabufo; Filomena Corbo; Elisabetta Casalino; Carlo Franchini; Isabella Pisano; Jean-François Desaphy; Antonio Carrieri; Alessia Carocci; Giovanni Lentini
Journal:  ChemMedChem       Date:  2021-10-05       Impact factor: 3.540

2.  Nondystrophic myotonia: challenges and future directions.

Authors:  Jaya R Trivedi; Stephen C Cannon; Robert C Griggs
Journal:  Exp Neurol       Date:  2013-12-18       Impact factor: 5.330

Review 3.  Rare neurological channelopathies--networks to study patients, pathogenesis and treatment.

Authors:  Joanna C Jen; Tetsuo Ashizawa; Robert C Griggs; Michael F Waters
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

4.  Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine.

Authors:  Jean-François Desaphy; Concetta Altamura; Savine Vicart; Bertrand Fontaine
Journal:  J Neuromuscul Dis       Date:  2021

5.  Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity.

Authors:  Michela De Bellis; Roberta Carbonara; Julien Roussel; Alessandro Farinato; Ada Massari; Sabata Pierno; Marilena Muraglia; Filomena Corbo; Carlo Franchini; Maria Rosaria Carratù; Annamaria De Luca; Diana Conte Camerino; Jean-François Desaphy
Journal:  Neuropharmacology       Date:  2016-10-13       Impact factor: 5.250

6.  Dual Action of Mexiletine and Its Pyrroline Derivatives as Skeletal Muscle Sodium Channel Blockers and Anti-oxidant Compounds: Toward Novel Therapeutic Potential.

Authors:  Michela De Bellis; Francesca Sanarica; Alessia Carocci; Giovanni Lentini; Sabata Pierno; Jean-François Rolland; Diana Conte Camerino; Annamaria De Luca
Journal:  Front Pharmacol       Date:  2018-01-12       Impact factor: 5.810
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.